Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment

Haiqin Liao; Chengcheng Niu

doi:10.3389/fbioe.2022.887463

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment

Front Bioeng Biotechnol. 2022 Apr 26:10:887463. doi: 10.3389/fbioe.2022.887463. eCollection 2022.

Authors

Haiqin Liao^{1

2}, Chengcheng Niu^{1

2}

Affiliations

¹ Department of Ultrasound Diagnosis, The Second Xiangya Hospital, Central South University, Changsha, China.
² Research Center of Ultrasonography, The Second Xiangya Hospital, Central South University, Changsha, China.

Abstract

Many cancers have evolved various mechanisms to evade immunological surveillance, such as the inhibitory immune checkpoint of the CD47-SIRPα signaling pathway. By targeting this signaling pathway, researchers have developed diverse nanovehicles with different loaded drugs and modifications in anticancer treatment. In this review, we present a brief overview of CD47-SIRPα interaction and nanomedicine. Then, we delve into recent applications of the CD47-SIRPα interaction as a target for nanomedicine-based antitumor treatment and its combination with other targeting pathway drugs and/or therapeutic approaches.

Keywords: SIRPα; cd47; immunotherapy; nanomedicine; tumor.

Publication types

Review